251 results on '"Villa-Forte A"'
Search Results
2. Vasculitis Mimics and Other Related Conditions
- Author
-
Springer, Jason M. and Villa-Forte, Alexandra
- Published
- 2023
- Full Text
- View/download PDF
3. Kawasaki Disease: A Systematic Review and Meta‐Analysis of Benefits and Harms of Common Treatments
- Author
-
Karen E. James, Mohamad A. Kalot, Nedaa M. Husainat, Anisha B. Dua, Kevin Byram, Jason M. Springer, Yih Chang Lin, Marat Turgunbaev, Alexandra Villa‐Forte, Mark Gorelik, Andy Abril, Carol Langford, Mehrdad Maz, Sharon A. Chung, and Reem A. Mustafa
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
Objective Kawasaki disease (KD) is a self‐limited vasculitis affecting medium‐sized vessels with a predilection for the coronary arteries. Although treatment reduces the likelihood of developing of coronary artery aneurysms, 5% of patients still develop aneurysms despite treatment, making KD the leading cause of acquired heart disease in children in the United States. Consequently, there is a great deal of interest in optimizing treatment regimens, particularly for higher‐risk patients, to decrease morbidity. The aim of this systematic review is to support the development of the American College of Rheumatology/Vasculitis Foundation for the diagnosis and management of KD, focusing on the more complex scenarios in which rheumatologists may become involved, such as high‐risk and refractory disease. Methods Eighty‐nine articles were considered for full review in this systematic literature review to address 16 Population, Intervention, Comparison, and Outcome questions related to KD. Data were abstracted in hierarchical fashion. Randomized control trials (RCTs) were considered first; if none were identified or if they contained insufficient information, comparative observational studies were then viewed, followed by single‐arm observational studies/single arms from comparative studies. Only observational studies with more than 10 subjects with vasculitis were included. Results Eight RCTs and 28 observational studies that addressed the questions were identified. Two questions were addressed by RCTs, seven questions had at least some comparative observational studies, three questions were only addressed by single‐arm data, and four questions had no relevant studies. Conclusion This systematic review evaluates the benefits and harms of treatments for KD beyond first‐line therapy.
- Published
- 2021
- Full Text
- View/download PDF
4. Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity
- Author
-
Cassandra Calabrese, Elizabeth Kirchner, Alexandra Villa-Forte, Rula A Hajj-Ali, Brandon P Moss, and James P Fernandez
- Subjects
Medicine - Published
- 2022
- Full Text
- View/download PDF
5. Giant Cell Arteritis: A Systematic Review and Meta‐Analysis of Test Accuracy and Benefits and Harms of Common Treatments
- Author
-
Anisha B. Dua, Nedaa M. Husainat, Mohamad A. Kalot, Kevin Byram, Jason M. Springer, Karen E. James, Yih Chang Lin, Marat Turgunbaev, Alexandra Villa‐Forte, Andy Abril, Carol Langford, Mehrdad Maz, Sharon A. Chung, and Reem A. Mustafa
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
This systematic review compares treatment options for patients with giant cell arteritis (GCA) and evaluates the test accuracy of studies used in diagnosing and monitoring GCA. These studies were used to inform evidence‐based recommendations for the American College of Rheumatology (ACR)/Vasculitis Foundation (VF) vasculitis management guidelines. A systematic review and search of articles in English in Ovid Medline, PubMed, Embase, and the Cochrane Library was conducted. Articles were screened for suitability, and studies presenting the highest level of evidence were given preference. Three hundred ninety‐nine full‐text articles addressing GCA questions were reviewed to inform 27 Population, Intervention, Comparison, and Outcome questions. No benefit was found with intravenous glucocorticoids (GCs) compared with high‐dose oral GCs in patients with cranial ischemic symptoms (27.4% vs 12.3%; odds ratio [OR] 2.39 [95% confidence interval (CI) 0.75‐7.62], [very low certainty of evidence]). Weekly tocilizumab with a 26‐week GC taper was superior to a 52‐week GC taper in patients achieving remission (risk ratio 4.00 [95% CI 1.97‐8.12], [low certainty of evidence]). Non‐GC immunosuppressive therapies with GCs compared with GCs alone showed no statistically significant in relapse at 1 year (OR 0.87 [95% CI 0.73‐1.04], [moderate certainty of evidence]) or serious adverse events (OR 0.81 [95% CI 0.54‐1.20]; [moderate certainty of evidence]). Temporal artery biopsy has a sensitivity of 61% (95% CI 38%‐79%) and a specificity of 98% (95% CI 95%‐99%) in patients with a clinical diagnosis of suspected GCA. This comprehensive systematic review synthesizes and evaluates the benefits and harms of different treatment options and the accuracy of commonly used tests for the diagnosis and monitoring of GCA.
- Published
- 2021
- Full Text
- View/download PDF
6. Granulomatosis With Polyangiitis and Microscopic Polyangiitis: A Systematic Review and Meta‐Analysis of Benefits and Harms of Common Treatments
- Author
-
Jason M. Springer, Mohamad A. Kalot, Nedaa M. Husainat, Kevin W. Byram, Anisha B. Dua, Karen E. James, Yih Chang Lin, Marat Turgunbaev, Alexandra Villa‐Forte, Andy Abril, Carol Langford, Mehrdad Maz, Sharon A. Chung, and Reem A. Mustafa
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
Objective The aim of this systemic review is to compare different treatments for patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) to inform evidence‐based recommendations for the American College of Rheumatology (ACR)/Vasculitis Foundation (VF) Vasculitis Management Guidelines. Methods A systemic review was conducted by searching articles in English using OVID Medline, PubMed, Embase, and the Cochrane Library. Articles were screened for suitability in addressing PICO questions, with studies presenting the highest level of evidence given preference. Results A total of 729 full‐text articles addressing GPA and MPA PICO questions were reviewed. For remission induction, rituximab was shown to be noninferior to cyclophosphamide (CYC) (odds ratio [OR]: 1.55, moderate certainty of evidence). The addition of plasma exchange to induction therapy in severe disease did not improve the composite end point of death or end stage renal disease (hazard ratio [HR]: 0.86 [95% confidence interval CI: 0.65, 1.13], moderate certainty of evidence). In nonsevere disease, methotrexate was noninferior to CYC for induction of remission (remission at 6 months of 90% vs. 94%). For maintenance of remission, methotrexate and azathioprine showed no difference in the risk of relapse over a mean follow‐up of 29 months (HR: 0.92, [95% CI: 0.52, 1.65]low certainty of evidence). As maintenance therapy, rituximab was superior to a tapering azathioprine strategy in major relapse‐free survival at 28 months (HR: 6.61, [95% CI: 1.56, 27.96], moderate certainty of evidence). In two randomized trials, longer‐term azathioprine maintenance therapy (>24 months) is associated with fewer relapses without an increase in adverse events. Conclusion This comprehensive systematic review synthesizes and evaluates the benefits and toxicities of different treatment options for GPA and MPA.
- Published
- 2021
- Full Text
- View/download PDF
7. Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta‐Analysis of Test Accuracy and Benefits and Harms of Common Treatments
- Author
-
Jason M. Springer, Mohamad A. Kalot, Nedaa M. Husainat, Kevin W. Byram, Anisha B. Dua, Karen E. James, Yih Chang Lin, Marat Turgunbaev, Alexandra Villa‐Forte, Andy Abril, Carol A. Langford, Mehrdad Maz, Sharon A. Chung, and Reem A. Mustafa
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
Objective Eosinophilic granulomatosis with polyangiitis (EGPA) is part of a group of vasculitides commonly referred to as antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV), in addition to granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and renal‐limited vasculitis. Patients with EGPA characteristically have asthma and marked peripheral eosinophilia with only approximately 30% to 35% of patients being myeloperoxidase (MPO)‐ANCA positive, distinguishing it from other forms of AAV (1,2). The aim of this systematic review is to support the development of the American College of Rheumatology/Vasculitis Foundation guideline for the management of EGPA. Methods A systematic review was conducted of the literature for seven forms of primary systemic vasculitis (GPA, MPA, EGPA, polyarteritis nodosa, Kawasaki disease, giant cell arteritis, and Takayasu arteritis). The search was done for articles in English using Ovid Medline, PubMed, Embase, and the Cochrane Library. Articles were screened for suitability in addressing population/patients, intervention, comparator, and outcomes (PICO) questions, with studies presenting the highest level of evidence given preference. Two independent reviewers conducted a title/abstract screen and full‐text review for each eligible study. Results The initial search, conducted in August 2019, included 13 800 articles, of which 2596 full‐text articles were reviewed. There were 190 articles (addressing 34 PICO questions) reporting on the diagnosis and management of EGPA. Conclusion This comprehensive systematic review synthesizes and evaluates the accuracy of commonly used tests for EGPA as well as benefits and toxicities of different treatment options.
- Published
- 2021
- Full Text
- View/download PDF
8. Takayasu Arteritis: a Systematic Review and Meta‐Analysis of Test Accuracy and Benefits and Harms of Common Treatments
- Author
-
Anisha B. Dua, Mohamad A. Kalot, Nedaa M. Husainat, Kevin Byram, Jason M. Springer, Karen E. James, Yih Chang Lin, Marat Turgunbaev, Alexandra Villa‐Forte, Andy Abril, Carol Langford, Mehrdad Maz, Sharon A. Chung, and Reem A. Mustafa
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
Objective Takayasu’s arteritis (TAK) is a granulomatous large‐vessel vasculitis primarily affecting the aorta and its proximal branches. TAK can be a difficult disease to diagnose and manage given the rarity of the disease as well as current limitations in biomarkers, imperfect imaging modalities, and few randomized controlled trials. Methods In developing the American College of Rheumatology/Vasculitis Foundation guideline for the management of TAK, we performed an extensive systematic literature review to guide our recommendations. We included RCTs first. When RCTs were not available, we included observational studies that reported on patient‐important outcomes for the intervention and comparison. When studies with comparative data were not available, we included case series that present patient‐important outcomes for either the intervention or the comparison. Results Three hundred forty‐seven articles were included for full review to answer 27 population, intervention, comparison, and outcome questions related to TAK. Ten studies were evaluated that addressed the use of glucocorticoids (GCs), non‐GC nonbiologic therapies, as well as biologics in treating TAK. A total of 33 studies, including 8 comparative studies, were included to determine the test accuracy of commonly available diagnostic tests for TAK. Conclusion This comprehensive systematic review synthesizes and evaluates the benefits and harms of different treatment options and the accuracy of commonly used tests for the management of TAK.
- Published
- 2021
- Full Text
- View/download PDF
9. Polyarteritis Nodosa: A Systematic Review of Test Accuracy and Benefits and Harms of Common Treatments
- Author
-
Yih Chang Lin, Mohamad A. Kalot, Nedaa M. Husainat, Kevin Byram, Anisha B. Dua, Karen E. James, Jason M. Springer, Marat Turgunbaev, Alexandra Villa‐Forte, Andy Abril, Carol Langford, Mehrdad Maz, Sharon A. Chung, and Reem A. Mustafa
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
Objective The object of this study was to analyze the benefits and harms of different treatment options and to analyze test accuracy used in the evaluation of patients with primary systemic polyarteritis nodosa (PAN). Methods A systematic search of published English‐language literature was performed in Ovid Medline, PubMed, Embase, and the Cochrane Library from the inception of each database through August 2019. Articles were screened for suitability in addressing patient, intervention, comparison, and outcome questions, with studies presenting the highest level of evidence given preference. Results Of 137 articles selected for data abstraction, we analyzed 21 observational studies and seven randomized controlled trials (RCTs). The results showed indirect evidence that a deep skin biopsy provides good diagnostic accuracy. A combined nerve and muscle biopsy should be obtained for patients with PAN with peripheral neuropathy. Cyclophosphamide with high‐dose glucocorticoids (GCs) is effective as an induction treatment for newly diagnosed active and severe PAN. GC monotherapy is adequate in the majority of patients with nonsevere PAN, although it has a high relapse rate with GC taper. There was insufficient data in determining the optimal duration of non‐GC and GC maintenance therapy. Tumor necrosis factor inhibitors are effective treatment for patients with deficiency of adenosine deaminase 2 (DADA2) with stroke and vasculitis manifestations. Conclusion This comprehensive systematic review synthesizes and evaluates the harms and benefits of different treatment options and the accuracy of commonly used tests for the diagnosis of systemic PAN. Data for diagnosis and management of PAN and DADA2 are mostly limited to observational studies. More high‐quality RCTs are needed.
- Published
- 2021
- Full Text
- View/download PDF
10. O texto nas malhas digitais e uma revisão da Escrita Conceitual – entrevista com Kenneth Goldsmith
- Author
-
Leonardo Villa-Forte and Lucas Murari
- Subjects
Escrita Conceitual ,Internet ,UbuWeb ,Literatura ,Novas Mídias ,Communication. Mass media ,P87-96 - Abstract
Entrevista inédita com Kenneth Goldsmith, escritor, poeta, artista e professor universitário.
- Published
- 2022
- Full Text
- View/download PDF
11. IgA Vasculitis in Adults: a Rare yet Challenging Disease
- Author
-
Yaseen, Kinanah, Herlitz, Leal C, and Villa-Forte, Alexandra
- Published
- 2021
- Full Text
- View/download PDF
12. Microbiomes of Inflammatory Thoracic Aortic Aneurysms Due to Giant Cell Arteritis and Clinically Isolated Aortitis Differ From Those of Non-Inflammatory Aneurysms
- Author
-
Ted M. Getz, Gary Stuart Hoffman, Roshan Padmanabhan, Alexandra Villa-Forte, Eric E. Roselli, Eugene Blackstone, Douglas Johnston, Gosta Pettersson, Edward Soltesz, Lars G. Svensson, Leonard H. Calabrese, Alison H. Clifford, and Charis Eng
- Subjects
aorta ,aneurysms ,aortitis ,microbiome ,clinically isolated aortitis ,giant cell arteritis ,Pathology ,RB1-214 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Objective: We sought to characterize microbiomes of thoracic aortas from patients with non-infectious aortitis due to giant cell arteritis (GCA) and clinically isolated aortitis (CIA) and to compare them to non-inflammatory aorta aneurysm controls. We also compared microbiomes from concurrently processed and separately reported temporal arteries (TA) and aortas. Methods: From 220 prospectively enrolled patients undergoing surgery for thoracic aorta aneurysm, 49 were selected. Inflammatory and non-inflammatory cases were selected based on ability to match for age (+/-10 years), gender, and race. Biopsies were collected under aseptic conditions and snap-frozen. Taxonomic classification of bacterial sequences was performed to the genus level and relative abundances were calculated. Microbiome differential abundances were analyzed by principal coordinates analysis. Results : Forty-nine patients with thoracic aortic aneurysms (12 CIA, 14 GCA, 23 non-inflammatory aneurysms) were enrolled. Alpha (P = 0.018) and beta (P = 0.024) diversity differed between specimens from aortitis cases and controls. There were no significant differences between CIA and GCA (P > 0.7). The largest differential abundances between non-infectious aortitis and non-inflammatory control samples includedEnterobacteriaceae, Phascolarctobacterium, Acinetobactor, Klebsiella, and Prevotella. Functional metagenomic predictions with PICRUSt revealed enrichment of oxidative phosphorylation and porphyrin metabolism pathways and downregulation of transcription factor pathways in aortitis compared to controls. Microbiomes of aortic samples differed significantly from temporal artery samples from a companion study, in both control and GCA groups (P = 0.0002). Conclusion: Thoracic aorta aneurysms, far from being sterile, contain unique microbiomes that differ from those found in temporal arteries. The aorta microbiomes are most similar between aneurysms that were associated with inflammation, GCA, and CIA, but differed from those associated with non-inflammatory etiologies. These findings are promising in that they indicate that microbes may play a role in the pathogenesis of aortitis-associated aneurysms or non-inflammatory aneurysms by promoting or protecting against inflammation. However, we cannot rule out that these changes are related to alterations in tissue substrate that favor secondary changes in microbial communities.
- Published
- 2019
- Full Text
- View/download PDF
13. The Microbiome of Temporal Arteries
- Author
-
Gary Stuart Hoffman, Ted M. Getz, Roshan Padmanabhan, Alexandra Villa-Forte, Alison H. Clifford, Pauline Funchain, Madhav Sankunny, Julian D. Perry, Alexander Blandford, Gregory Kosmorsky, Lisa Lystad, Leonard H. Calabrese, and Charis Eng
- Subjects
vasculitis ,giant cell arteritis ,microbiome ,Pathology ,RB1-214 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Objective: A role for microorganisms in giant cell arteritis (GCA) has long been suspected. We describe the microbiomes of temporal arteries from patients with GCA and controls. Methods: Temporal artery biopsies from patients suspected to have GCA were collected under aseptic conditions and snap-frozen. Fluorescence in situ hybridization (FISH) and long-read 16S rRNA-gene sequencing was used to examine microbiomes of temporal arteries. Taxonomic classification of bacterial sequences was performed to the genus level and relative abundances were calculated. Microbiome differential abundances were analyzed by principal coordinate analysis (PCoA) with comparative Unifrac distances and predicted functional profiling using PICRUSt. Results : Forty-seven patients, including 9 with biopsy-positive GCA, 15 with biopsy-negative GCA and 23 controls without GCA, were enrolled. FISH for bacterial DNA revealed signal in the arterial media. Beta, but not alpha, diversity differed between GCA and control temporal arteries (P = 0.042). Importantly, there were no significant differences between biopsy-positive and biopsy-negative GCA (P > 0.99). The largest differential abundances seen between GCA and non-GCA temporal arteries included Proteobacteria (P), Bifidobacterium (g), Parasutterella (g) and Granulicatella (g) [Log 2-fold change > 4]. Conclusion: Temporal arteries are not sterile, but rather are inhabited by a community of bacteria. We have demonstrated that there are microbiomic differences between GCA and non-GCA temporal arteries, but not between biopsy-positive and biopsy-negative GCA.
- Published
- 2019
- Full Text
- View/download PDF
14. Eosinophilic granulomatosis with polyangiitis
- Author
-
Alexandra, Villa-Forte
- Subjects
General Medicine - Abstract
This review aims to describe the epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prognosis of eosinophilic granulomatosis with polyangiitis (EGPA). Eosinophilic granulomatosis with polyangiitis is a small to medium vessel necrotizing vasculitis, typically classified with granulomatosis with polyangiitis (GPA) and microscopic polyangitis (MPA) as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, less than 50% of patients with EGPA have a positive ANCA test. Among all the vasculitides, asthma and eosinophilia are unique features of EGPA. Eosinophilic granulomatosis with polyangiitis is very rare and the diagnosis may be missed as the disease evolves over time. Polyneuropathies are common and may be severe, requiring aggressive immunosuppressive therapy. Heart involvement is the most common cause of death in EGPA. Biopsy of involved tissue supports a clinically suspected diagnosis but is not always feasible. Treatment of EGPA is primarily dictated by the severity of disease and prognostic factors. More severe disease frequently requires the use of aggressive therapy such as cyclophosphamide. Once treatment is initiated, patients can achieve good control of symptoms; unfortunately, disease relapses are common and prolonged treatment with corticosteroids is often necessary for asthma management. A better understanding of the disease heterogeneity is needed for the development of better therapies.
- Published
- 2022
- Full Text
- View/download PDF
15. Granulomatosis with Polyangiitis (GPA)
- Author
-
Pagnoux, Christian, Villa-Forte, Alexandra, and Parnham, Michael J., editor
- Published
- 2016
- Full Text
- View/download PDF
16. Granulomatosis with Polyangiitis (Wegener’s Granulomatosis)
- Author
-
Pagnoux, Christian, Villa-Forte, Alexandra, Cottin, Vincent, editor, Cordier, Jean-Francois, editor, and Richeldi, Luca, editor
- Published
- 2015
- Full Text
- View/download PDF
17. Varicella Zoster Virus and Large Vessel Vasculitis, the Absence of an Association
- Author
-
Gary W. Procop, Charis Eng, Alison Clifford, Alexandra Villa-Forte, Leonard H. Calabrese, Eric Roselli, Lars Svensson, Douglas Johnston, Gosta Pettersson, Edward Soltesz, Lisa Lystad, Julian D. Perry, Alexander Blandford, Deborah A. Wilson, and Gary S. Hoffman
- Subjects
Aorta and temporal artery biopsies, Varicella Zoster Virus, Large Vessel Vasculitis ,Pathology ,RB1-214 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Objective: It is controversial whether microorganisms play a role in the pathogenesis of large and medium vessel vasculitides (eg, giant cell arteritis [GCA], Takayasu arteritis [TAK] and focal idiopathic aortitis [FIA]). Recent studies have reported the presence of Varicella Zoster Virus (VZV) within formalin-fixed, paraffin-embedded temporal arteries and aortas of about three-quarters or more of patients with these conditions, and in a minority of controls. In a prospective study, we sought to confirm these findings using DNA extracted from vessels that were harvested under surgically aseptic conditions and snap frozen. Methods and Results: DNA samples extracted from 11 surgically sterile temporal arteries and 31 surgically sterile thoracic aortas were used in an attempt to identify the vessel-associated VZV genome. Two different validated PCR methods were used. Thirty-one thoracic aorta aneurysm specimens included biopsies from 8 patients with GCA, 2 from patients with TAK, 6 from patients with FIA, and 15 from patients without vasculitis, who had non-inflammatory aneurysms. Eleven temporal artery biopsies were collected from 5 patients with GCA and 6 controls. The presence of VZV was not identified in either the specimens from patients with large vessel vasculitis or from the controls. Conclusions: Using surgically sterile snap-frozen specimens, we were unable to confirm recent reports of the presence of VZV in either aortas or temporal arteries from patients with large vessel vasculitis or controls. Keywords: Aorta and temporal artery biopsies, Varicella Zoster Virus, Large Vessel Vasculitis
- Published
- 2017
- Full Text
- View/download PDF
18. Voz e expressão na escrita recriativa = Voice and expression in uncreative writing
- Author
-
Villa-Forte, Leonardo
- Subjects
escrita criativa ,Literature (General) ,PN1-6790 ,French literature - Italian literature - Spanish literature - Portuguese literature ,PQ1-3999 - Abstract
O artigo aborda os poemas com auxílio do Google, de Angélica Freitas; as obras Traffic, Sports e Weather, de Kenneth Goldsmith; Sessão, de Roy David Frankel, e Tree of Codes, de Jonathan Safran Foer, a partir da ótica da chamada “escrita recriativa”. Discutiremos como, por meio dessas, manifesta-se ou não uma possível voz de autor e sua expressão individual, além de como tal voz e tal expressão atuam nas mesmas. Partindo do pensamento de autores como Antoine Compagnon e Roland Barthes, veremos algumas diferenças daquilo que eles postularam sobre a figura do autor e sua voz e a composição de um texto sob as novas condições da era digital
- Published
- 2017
19. Correntes espirituais em diálogo
- Author
-
Wolff, Elias, primary and Villa Forte, Marcelo, additional
- Published
- 2023
- Full Text
- View/download PDF
20. Appropriation writing in a post-production context
- Author
-
Leonardo Nabuco Villa-Forte
- Subjects
Apropriação ,autoria ,montagem ,literatura ,arte. ,Literature (General) ,PN1-6790 ,French literature - Italian literature - Spanish literature - Portuguese literature ,PQ1-3999 - Abstract
Increasingly, it is possible to see texts which are not the product of their authors, but rather an appropriation they make of excerpts or even whole pieces of another author’s work or other sources such as radiophonic broadcasts and newspaper issues. In 2007, the French curator Nicolas Bourriaud proposed the term “post-production” to group together artworks following Marcel Duchamp’s concept of “ready-made”. In 2011, the poet and artist Kenneth Goldsmith, who is also a professor at the University of Pennsylvania, formulated the notion of “uncreative writing”, thus moving a similar idea into the textual milieu. Based on these assertions, the aim of this paper is to find out where such practices point to and how they can be conceived in a wider context of contemporaneity, in a dialogue with the Internet and the colossal amount of information it makes available.
- Published
- 2016
21. Vasculitis Mimics and Other Related Conditions
- Author
-
Jason M. Springer and Alexandra Villa-Forte
- Subjects
Rheumatology - Published
- 2023
- Full Text
- View/download PDF
22. The Excessively Clotting Cancer Patient
- Author
-
Gomes, Marcelo P. Villa-Forte, Lichtin, Alan, editor, and Bartholomew, John, editor
- Published
- 2014
- Full Text
- View/download PDF
23. texto nas malhas digitais e uma revisão da Escrita Conceitual – entrevista com Kenneth Goldsmith
- Author
-
Leonardo Villa-Forte and Lucas Murari
- Subjects
General Medicine - Abstract
Entrevista inédita com Kenneth Goldsmith, escritor, poeta, artista e professor universitário.
- Published
- 2022
- Full Text
- View/download PDF
24. Granulomatosis with Polyangiitis
- Author
-
Christian Pagnoux and Alexandra Villa-Forte
- Published
- 2023
- Full Text
- View/download PDF
25. Eosinophilic Granulomatosis with Polyangiitis
- Author
-
Villa-Forte, Alexandra, primary
- Published
- 2022
- Full Text
- View/download PDF
26. Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity
- Author
-
Calabrese, Cassandra, primary, Kirchner, Elizabeth, additional, Villa-Forte, Alexandra, additional, Hajj-Ali, Rula A, additional, Moss, Brandon P, additional, Fernandez, James P, additional, and Calabrese, Leonard, additional
- Published
- 2022
- Full Text
- View/download PDF
27. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
- Author
-
Yih Chang Lin, Maria Ibarra, Robert P. Sundel, Amy S. Turner, Ann Warner, Carol A. Langford, Andy Abril, Gordon H. Guyatt, Doyt L. Conn, Amy M. Archer, John H. Stone, Nedaa Husainat, Kathy A. Full, Reem A. Mustafa, Kevin Byram, Jason M. Springer, Rennie L. Rhee, Anisha B. Dua, Mohamad A. Kalot, Peter A. Merkel, Marat Turgunbaev, Sangeeta Sule, Mehrdad Maz, Susan Kim, Sharon A. Chung, Mark Gorelik, Peter C. Grayson, Omar I. Vitobaldi, Philip Seo, Alexandra Villa-Forte, Lisa Imundo, and Karen E. James
- Subjects
medicine.medical_specialty ,Consensus ,Clinical Decision-Making ,Immunology ,Population ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ,Severity of Illness Index ,Antibodies, Antineutrophil Cytoplasmic ,Decision Support Techniques ,Rheumatology ,Maintenance therapy ,medicine ,Humans ,Immunology and Allergy ,Intensive care medicine ,education ,Anti-neutrophil cytoplasmic antibody ,education.field_of_study ,Evidence-Based Medicine ,business.industry ,Guideline ,medicine.disease ,Treatment Outcome ,Adjunctive treatment ,Microscopic polyangiitis ,business ,Granulomatosis with polyangiitis ,Mepolizumab ,Biomarkers ,Immunosuppressive Agents ,medicine.drug - Abstract
Objective To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Methods Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low-quality evidence supporting the recommendations. Conclusion This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.
- Published
- 2021
- Full Text
- View/download PDF
28. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis
- Author
-
Yih Chang Lin, Kevin Byram, Peter C. Grayson, Kathy A. Full, Jason M. Springer, Sharon A. Chung, Robert P. Sundel, Marat Turgunbaev, Maria Ibarra, Sangeeta Sule, Rennie L. Rhee, Amy S. Turner, Mark Gorelik, Mohamad A. Kalot, Peter A. Merkel, Carol A. Langford, Nedaa Husainat, Mehrdad Maz, Ann Warner, Amy M. Archer, Andy Abril, Doyt L. Conn, Karen E. James, Reem A. Mustafa, Anisha B. Dua, Philip Seo, Alexandra Villa-Forte, Gordon H. Guyatt, John H. Stone, Susan Kim, Lisa Imundo, and Omar I. Vitobaldi
- Subjects
medicine.medical_specialty ,Consensus ,Clinical Decision-Making ,Giant Cell Arteritis ,Immunology ,Population ,MEDLINE ,Decision Support Techniques ,Rheumatology ,Internal medicine ,Humans ,Immunology and Allergy ,Medicine ,Disease management (health) ,skin and connective tissue diseases ,Intensive care medicine ,education ,Grading (education) ,Glucocorticoids ,education.field_of_study ,Evidence-Based Medicine ,business.industry ,Disease Management ,Guideline ,medicine.disease ,Takayasu Arteritis ,United States ,Giant cell arteritis ,Treatment Outcome ,Drug Therapy, Combination ,business ,Vasculitis ,Immunosuppressive Agents - Abstract
Objective To provide evidence-based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. Methods Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. Recommendations were developed by the Voting Panel, comprising adult and pediatric rheumatologists and patients. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 22 recommendations and 2 ungraded position statements for GCA, and 20 recommendations and 1 ungraded position statement for TAK. These recommendations and statements address clinical questions relating to the use of diagnostic testing, including imaging, treatments, and surgical interventions in GCA and TAK. Recommendations for GCA include support for the use of glucocorticoid-sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of nonglucocorticoid immunosuppressive agents with glucocorticoids as initial therapy. There were only 2 strong recommendations; the remaining recommendations were conditional due to the low quality of evidence available for most PICO questions. Conclusion These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.
- Published
- 2021
- Full Text
- View/download PDF
29. Giant Cell Arteritis: A Systematic Review and Meta‐Analysis of Test Accuracy and Benefits and Harms of Common Treatments
- Author
-
Mehrdad Maz, Jason M. Springer, Anisha B. Dua, Karen E. James, Kevin Byram, Reem A. Mustafa, Nedaa Husainat, Marat Turgunbaev, Carol A. Langford, Mohamad A. Kalot, Andy Abril, Yih Chang Lin, Alexandra Villa-Forte, and Sharon A. Chung
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,Population ,Diseases of the musculoskeletal system ,Review Article ,Odds ratio ,Cochrane Library ,medicine.disease ,Confidence interval ,Giant cell arteritis ,RC925-935 ,Rheumatology ,Internal medicine ,Relative risk ,Meta-analysis ,medicine ,business ,Vasculitis ,education ,Review Articles - Abstract
This systematic review compares treatment options for patients with giant cell arteritis (GCA) and evaluates the test accuracy of studies used in diagnosing and monitoring GCA. These studies were used to inform evidence‐based recommendations for the American College of Rheumatology (ACR)/Vasculitis Foundation (VF) vasculitis management guidelines. A systematic review and search of articles in English in Ovid Medline, PubMed, Embase, and the Cochrane Library was conducted. Articles were screened for suitability, and studies presenting the highest level of evidence were given preference. Three hundred ninety‐nine full‐text articles addressing GCA questions were reviewed to inform 27 Population, Intervention, Comparison, and Outcome questions. No benefit was found with intravenous glucocorticoids (GCs) compared with high‐dose oral GCs in patients with cranial ischemic symptoms (27.4% vs 12.3%; odds ratio [OR] 2.39 [95% confidence interval (CI) 0.75‐7.62], [very low certainty of evidence]). Weekly tocilizumab with a 26‐week GC taper was superior to a 52‐week GC taper in patients achieving remission (risk ratio 4.00 [95% CI 1.97‐8.12], [low certainty of evidence]). Non‐GC immunosuppressive therapies with GCs compared with GCs alone showed no statistically significant in relapse at 1 year (OR 0.87 [95% CI 0.73‐1.04], [moderate certainty of evidence]) or serious adverse events (OR 0.81 [95% CI 0.54‐1.20]; [moderate certainty of evidence]). Temporal artery biopsy has a sensitivity of 61% (95% CI 38%‐79%) and a specificity of 98% (95% CI 95%‐99%) in patients with a clinical diagnosis of suspected GCA. This comprehensive systematic review synthesizes and evaluates the benefits and harms of different treatment options and the accuracy of commonly used tests for the diagnosis and monitoring of GCA.
- Published
- 2021
- Full Text
- View/download PDF
30. Granulomatosis With Polyangiitis and Microscopic Polyangiitis: A Systematic Review and Meta‐Analysis of Benefits and Harms of Common Treatments
- Author
-
Anisha B. Dua, Sharon A. Chung, Marat Turgunbaev, Nedaa Husainat, Karen E. James, Mohamad A. Kalot, Mehrdad Maz, Jason M. Springer, Kevin Byram, Alexandra Villa-Forte, Yih Chang Lin, Carol A. Langford, Andy Abril, and Reem A. Mustafa
- Subjects
medicine.medical_specialty ,lcsh:Diseases of the musculoskeletal system ,business.industry ,Hazard ratio ,Azathioprine ,Original Articles ,Cochrane Library ,medicine.disease ,End stage renal disease ,Rheumatology ,Maintenance therapy ,Internal medicine ,medicine ,Original Article ,Rituximab ,lcsh:RC925-935 ,Microscopic polyangiitis ,Granulomatosis with polyangiitis ,business ,medicine.drug - Abstract
Objective The aim of this systemic review is to compare different treatments for patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) to inform evidence-based recommendations for the American College of Rheumatology (ACR)/Vasculitis Foundation (VF) Vasculitis Management Guidelines. Methods A systemic review was conducted by searching articles in English using OVID Medline, PubMed, Embase, and the Cochrane Library. Articles were screened for suitability in addressing PICO questions, with studies presenting the highest level of evidence given preference. Results A total of 729 full-text articles addressing GPA and MPA PICO questions were reviewed. For remission induction, rituximab was shown to be noninferior to cyclophosphamide (CYC) (odds ratio [OR]: 1.55, moderate certainty of evidence). The addition of plasma exchange to induction therapy in severe disease did not improve the composite end point of death or end stage renal disease (hazard ratio [HR]: 0.86 [95% confidence interval CI: 0.65, 1.13], moderate certainty of evidence). In nonsevere disease, methotrexate was noninferior to CYC for induction of remission (remission at 6 months of 90% vs. 94%). For maintenance of remission, methotrexate and azathioprine showed no difference in the risk of relapse over a mean follow-up of 29 months (HR: 0.92, [95% CI: 0.52, 1.65]low certainty of evidence). As maintenance therapy, rituximab was superior to a tapering azathioprine strategy in major relapse-free survival at 28 months (HR: 6.61, [95% CI: 1.56, 27.96], moderate certainty of evidence). In two randomized trials, longer-term azathioprine maintenance therapy (>24 months) is associated with fewer relapses without an increase in adverse events. Conclusion This comprehensive systematic review synthesizes and evaluates the benefits and toxicities of different treatment options for GPA and MPA.
- Published
- 2021
- Full Text
- View/download PDF
31. Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta‐Analysis of Test Accuracy and Benefits and Harms of Common Treatments
- Author
-
Reem A. Mustafa, Kevin Byram, Mohamad A. Kalot, Mehrdad Maz, Anisha B. Dua, Sharon A. Chung, Carol A. Langford, Andy Abril, Yih Chang Lin, Nedaa Husainat, Marat Turgunbaev, Alexandra Villa-Forte, Karen E. James, and Jason M. Springer
- Subjects
education.field_of_study ,medicine.medical_specialty ,lcsh:Diseases of the musculoskeletal system ,Polyarteritis nodosa ,business.industry ,Population ,Original Articles ,medicine.disease ,Dermatology ,Rheumatology ,medicine ,Kawasaki disease ,Original Article ,lcsh:RC925-935 ,Vasculitis ,Microscopic polyangiitis ,Granulomatosis with polyangiitis ,education ,business ,Anti-neutrophil cytoplasmic antibody ,Systemic vasculitis - Abstract
OBJECTIVE Eosinophilic granulomatosis with polyangiitis (EGPA) is part of a group of vasculitides commonly referred to as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), in addition to granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and renal-limited vasculitis. Patients with EGPA characteristically have asthma and marked peripheral eosinophilia with only approximately 30% to 35% of patients being myeloperoxidase (MPO)-ANCA positive, distinguishing it from other forms of AAV (1,2). The aim of this systematic review is to support the development of the American College of Rheumatology/Vasculitis Foundation guideline for the management of EGPA. METHODS A systematic review was conducted of the literature for seven forms of primary systemic vasculitis (GPA, MPA, EGPA, polyarteritis nodosa, Kawasaki disease, giant cell arteritis, and Takayasu arteritis). The search was done for articles in English using Ovid Medline, PubMed, Embase, and the Cochrane Library. Articles were screened for suitability in addressing population/patients, intervention, comparator, and outcomes (PICO) questions, with studies presenting the highest level of evidence given preference. Two independent reviewers conducted a title/abstract screen and full-text review for each eligible study. RESULTS The initial search, conducted in August 2019, included 13 800 articles, of which 2596 full-text articles were reviewed. There were 190 articles (addressing 34 PICO questions) reporting on the diagnosis and management of EGPA. CONCLUSION This comprehensive systematic review synthesizes and evaluates the accuracy of commonly used tests for EGPA as well as benefits and toxicities of different treatment options.
- Published
- 2021
32. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease
- Author
-
Gorelik, Mark, primary, Chung, Sharon A., additional, Ardalan, Kaveh, additional, Binstadt, Bryce A., additional, Friedman, Kevin, additional, Hayward, Kristen, additional, Imundo, Lisa F., additional, Lapidus, Sivia K., additional, Kim, Susan, additional, Son, Mary Beth, additional, Sule, Sangeeta, additional, Tremoulet, Adriana H., additional, Van Mater, Heather, additional, Yildirim‐Toruner, Cagri, additional, Langford, Carol A., additional, Maz, Mehrdad, additional, Abril, Andy, additional, Guyatt, Gordon, additional, Archer, Amy M., additional, Conn, Doyt L., additional, Full, Kathy A., additional, Grayson, Peter C., additional, Ibarra, Maria F., additional, Merkel, Peter A., additional, Rhee, Rennie L., additional, Seo, Philip, additional, Stone, John H., additional, Sundel, Robert P., additional, Vitobaldi, Omar I., additional, Warner, Ann, additional, Byram, Kevin, additional, Dua, Anisha B., additional, Husainat, Nedaa, additional, James, Karen E., additional, Kalot, Mohamad, additional, Lin, Yih Chang, additional, Springer, Jason M., additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Turner, Amy S., additional, and Mustafa, Reem A., additional
- Published
- 2022
- Full Text
- View/download PDF
33. Granulomatosis with Polyangiitis (GPA)
- Author
-
Pagnoux, Christian, primary and Villa-Forte, Alexandra, additional
- Published
- 2016
- Full Text
- View/download PDF
34. Recurrence rate of venous thromboembolic events in granulomatosis with polyangiitis
- Author
-
Alana, Nevares, Kinanah, Yaseen, Hiromichi, Tamaki, James, Bena, William, Messner, and Alexandra, Villa-Forte
- Subjects
Rheumatology - Abstract
Objective The incidence of first-time venous thromboembolic events (VTEs) is high in granulomatosis with polyangiitis (GPA). The incidence of recurrent VTEs is unknown. We aimed to describe the recurrence rate of second VTEs in patients with GPA. Methods Retrospective chart review was performed in patients with GPA and at least one VTE at a single centre from 2002 to 2016. Inclusion criteria were 1990 ACR criteria or 2012 Revised International Chapel Hill nomenclature for GPA, at least two follow-up visits, at least one VTE during the study period, and VTE occurrence after or within 3 months before GPA diagnosis. Second VTE event-free survival rates were estimated. Results Out of 147 patients initially screened for GPA and with at least one VTE, 84 met inclusion criteria. Median age at first VTE was 57 years. Incidence rate for second VTE was 8.4 events per 100 patient-years (95% CI: 5.7, 12.3). Eighty-three point three per cent of first VTEs and 57.7% of second VTEs occurred when disease was active (P Conclusion GPA has a high rate of VTE recurrence compared with the reported data in the general population with unprovoked VTE. Our results suggest that VTE in GPA is a recurrent co-morbidity, not always during active vasculitis, and more so in those with renal involvement and constitutional symptoms at the time of first VTE.
- Published
- 2022
- Full Text
- View/download PDF
35. Cardiovascular Disorders and Rheumatic Disease
- Author
-
Villa-Forte, Alexandra and Mandell, Brian F.
- Published
- 2011
- Full Text
- View/download PDF
36. texto nas malhas digitais e uma revisão da Escrita Conceitual – entrevista com Kenneth Goldsmith
- Author
-
Villa-Forte, Leonardo, primary and Murari, Lucas, additional
- Published
- 2022
- Full Text
- View/download PDF
37. Recurrence rate of venous thromboembolic events in granulomatosis with polyangiitis
- Author
-
Nevares, Alana, primary, Yaseen, Kinanah, additional, Tamaki, Hiromichi, additional, Bena, James, additional, Messner, William, additional, and Villa-Forte, Alexandra, additional
- Published
- 2022
- Full Text
- View/download PDF
38. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease
- Author
-
Mark Gorelik, Sharon A. Chung, Kaveh Ardalan, Bryce A. Binstadt, Kevin Friedman, Kristen Hayward, Lisa F. Imundo, Sivia K. Lapidus, Susan Kim, Mary Beth Son, Sangeeta Sule, Adriana H. Tremoulet, Heather Van Mater, Cagri Yildirim‐Toruner, Carol A. Langford, Mehrdad Maz, Andy Abril, Gordon Guyatt, Amy M. Archer, Doyt L. Conn, Kathy A. Full, Peter C. Grayson, Maria F. Ibarra, Peter A. Merkel, Rennie L. Rhee, Philip Seo, John H. Stone, Robert P. Sundel, Omar I. Vitobaldi, Ann Warner, Kevin Byram, Anisha B. Dua, Nedaa Husainat, Karen E. James, Mohamad Kalot, Yih Chang Lin, Jason M. Springer, Marat Turgunbaev, Alexandra Villa‐Forte, Amy S. Turner, and Reem A. Mustafa
- Subjects
Evidence-Based Medicine ,Rheumatology ,Immunology ,Immunology and Allergy ,Humans ,Immunoglobulins, Intravenous ,Mucocutaneous Lymph Node Syndrome ,Immunosuppressive Agents ,United States - Abstract
To provide evidence-based recommendations and expert guidance for the management of Kawasaki disease (KD), focusing on clinical scenarios more commonly addressed by rheumatologists.Sixteen clinical questions regarding diagnostic testing, treatment, and management of KD were developed in the Patient/Population, Intervention, Comparison, and Outcomes (PICO) question format. Systematic literature reviews were conducted for each PICO question. We used the Grading of Recommendations, Assessment, Development and Evaluation method to assess the quality of evidence and formulate recommendations. Each recommendation required consensus from at least 70% of the Voting Panel.We present 1 good practice statement, 11 recommendations, and 1 ungraded position statement to guide the management of KD and clinical scenarios of suspected KD. These recommendations for KD are focused on situations in which input from rheumatologists may be requested by other managing specialists, such as in cases of treatment-refractory, severe, or complicated KD. The good practice statement affirms that all patients with KD should receive initial treatment with intravenous immunoglobulin (IVIG). In addition, we developed 7 strong and 4 conditional recommendations for the management of KD or suspected KD. Strong recommendations include prompt treatment of incomplete KD, treatment with aspirin, and obtaining an echocardiogram in the setting of unexplained macrophage activation syndrome or shock. Conditional recommendations include use of IVIG with other adjuvant agents for patients with KD and high-risk features of IVIG resistance and/or coronary artery aneurysms. These recommendations endorse minimizing risk to the patient by using established therapy promptly at disease onset and identifying situations in which adjunctive therapy may be warranted.These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and use of echocardiography in patients with suspected or confirmed KD.
- Published
- 2021
39. Eosinophilic granulomatosis with polyangiitis.
- Author
-
Villa-Forte, Alexandra
- Subjects
CHURG-Strauss syndrome ,DISEASE relapse ,PROGNOSIS ,SYMPTOMS ,ANTINEUTROPHIL cytoplasmic antibodies - Abstract
This review aims to describe the epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prognosis of eosinophilic granulomatosis with polyangiitis (EGPA). Eosinophilic granulomatosis with polyangiitis is a small to medium vessel necrotizing vasculitis, typically classified with granulomatosis with polyangiitis (GPA) and microscopic polyangitis (MPA) as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, less than 50% of patients with EGPA have a positive ANCA test. Among all the vasculitides, asthma and eosinophilia are unique features of EGPA. Eosinophilic granulomatosis with polyangiitis is very rare and the diagnosis may be missed as the disease evolves over time. Polyneuropathies are common and may be severe, requiring aggressive immunosuppressive therapy. Heart involvement is the most common cause of death in EGPA. Biopsy of involved tissue supports a clinically suspected diagnosis but is not always feasible. Treatment of EGPA is primarily dictated by the severity of disease and prognostic factors. More severe disease frequently requires the use of aggressive therapy such as cyclophosphamide. Once treatment is initiated, patients can achieve good control of symptoms; unfortunately, disease relapses are common and prolonged treatment with corticosteroids is often necessary for asthma management. A better understanding of the disease heterogeneity is needed for the development of better therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Granulomatosis with Polyangiitis (Wegener’s Granulomatosis)
- Author
-
Pagnoux, Christian, primary and Villa-Forte, Alexandra, additional
- Published
- 2014
- Full Text
- View/download PDF
41. Systemic Vasculitis Syndromes
- Author
-
Alexandra Villa-Forte and Brian F. Mandell
- Subjects
medicine.medical_specialty ,business.industry ,medicine ,medicine.disease ,business ,Dermatology ,Systemic vasculitis - Published
- 2021
- Full Text
- View/download PDF
42. Microbiomes of Inflammatory Thoracic Aortic Aneurysms Due to Giant Cell Arteritis and Clinically Isolated Aortitis Differ From Those of Non-Inflammatory Aneurysms
- Author
-
Douglas R. Johnston, Gary S. Hoffman, Leonard H. Calabrese, Alexandra Villa-Forte, Eric E. Roselli, Alison H. Clifford, Edward G. Soltesz, Gösta B. Pettersson, Roshan Padmanabhan, Charis Eng, Lars G. Svensson, Eugene H. Blackstone, and Ted M Getz
- Subjects
Microbiology (medical) ,lcsh:Immunologic diseases. Allergy ,Pathology ,medicine.medical_specialty ,clinically isolated aortitis ,Immunology ,microbiome ,Pathogenesis ,03 medical and health sciences ,0302 clinical medicine ,Aneurysm ,aneurysms ,medicine.artery ,medicine ,Prevotella ,lcsh:Pathology ,Immunology and Allergy ,Thoracic aorta ,cardiovascular diseases ,Molecular Biology ,Aortitis ,030304 developmental biology ,030203 arthritis & rheumatology ,0303 health sciences ,Aorta ,biology ,business.industry ,giant cell arteritis ,medicine.disease ,biology.organism_classification ,Giant cell arteritis ,aorta ,Infectious Diseases ,Etiology ,cardiovascular system ,business ,lcsh:RC581-607 ,aortitis ,Research Article ,lcsh:RB1-214 - Abstract
Objective: We sought to characterize microbiomes of thoracic aortas from patients with non-infectious aortitis due to giant cell arteritis (GCA) and clinically isolated aortitis (CIA) and to compare them to non-inflammatory aorta aneurysm controls. We also compared microbiomes from concurrently processed and separately reported temporal arteries (TA) and aortas. Methods: From 220 prospectively enrolled patients undergoing surgery for thoracic aorta aneurysm, 49 were selected. Inflammatory and non-inflammatory cases were selected based on ability to match for age (+/-10 years), gender, and race. Biopsies were collected under aseptic conditions and snap-frozen. Taxonomic classification of bacterial sequences was performed to the genus level and relative abundances were calculated. Microbiome differential abundances were analyzed by principal coordinates analysis. Results : Forty-nine patients with thoracic aortic aneurysms (12 CIA, 14 GCA, 23 non-inflammatory aneurysms) were enrolled. Alpha ( P = 0.018) and beta ( P = 0.024) diversity differed between specimens from aortitis cases and controls. There were no significant differences between CIA and GCA ( P > 0.7). The largest differential abundances between non-infectious aortitis and non-inflammatory control samples included Enterobacteriaceae , Phascolarctobacterium , Acinetobactor , Klebsiella , and Prevotella. Functional metagenomic predictions with PICRUSt revealed enrichment of oxidative phosphorylation and porphyrin metabolism pathways and downregulation of transcription factor pathways in aortitis compared to controls. Microbiomes of aortic samples differed significantly from temporal artery samples from a companion study, in both control and GCA groups ( P = 0.0002). Conclusion: Thoracic aorta aneurysms, far from being sterile, contain unique microbiomes that differ from those found in temporal arteries. The aorta microbiomes are most similar between aneurysms that were associated with inflammation, GCA, and CIA, but differed from those associated with non-inflammatory etiologies. These findings are promising in that they indicate that microbes may play a role in the pathogenesis of aortitis-associated aneurysms or non-inflammatory aneurysms by promoting or protecting against inflammation. However, we cannot rule out that these changes are related to alterations in tissue substrate that favor secondary changes in microbial communities.
- Published
- 2019
43. Role of non-invasive multimodality imaging in autoimmune pericarditis
- Author
-
Paul Cremer, Bryce Montane, Massimo Imazio, Agam Bansal, Salaam P Bachour, Michael Chetrit, Allan L. Klein, Wilbert S. Aronow, Alexandra Villa Forte, Felix Berglund, Garvit Chhabra, Apostolos Kontzias, Vardhmaan Jain, and Muhammad M Furqaan
- Subjects
medicine.medical_specialty ,Systemic disease ,030204 cardiovascular system & hematology ,medicine.disease_cause ,Multimodal Imaging ,Pericardial Effusion ,030218 nuclear medicine & medical imaging ,Imaging modalities ,Autoimmunity ,03 medical and health sciences ,Pericarditis ,0302 clinical medicine ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Intensive care medicine ,medicine.diagnostic_test ,business.industry ,Non invasive ,Pericarditis, Constrictive ,Magnetic resonance imaging ,General Medicine ,medicine.disease ,Pericardial sac ,Etiology ,Cardiology and Cardiovascular Medicine ,business ,Pericardium - Abstract
Systemic autoimmune diseases are an important cause of pericardial involvement and contribute to up to ∼22% cases of pericarditis with a known aetiology. The underlying mechanism for pericardial involvement varies with each systemic disease and leads to a poor understanding of its management. Multimodality imaging establishes the diagnosis and determines the type and extent of pericardial involvement. In this review, we elaborate upon various pericardial syndromes associated with different systemic autoimmune and autoinflammatory diseases and the multitude of imaging modalities that can be used to further characterize autoimmune pericardial involvement. Lastly, these forms of pericarditis have a greater likelihood of recurrence, and clinicians need to understand their unique treatment approaches to improve patient outcomes.
- Published
- 2021
44. Systemic Vasculitis Syndromes
- Author
-
Villa-Forte, Alexandra, primary and Mandell, Brian F, primary
- Published
- 2021
- Full Text
- View/download PDF
45. Kawasaki Disease: A Systematic Review and Meta‐Analysis of Benefits and Harms of Common Treatments
- Author
-
James, Karen E., primary, Kalot, Mohamad A., additional, Husainat, Nedaa M., additional, Dua, Anisha B., additional, Byram, Kevin, additional, Springer, Jason M., additional, Lin, Yih Chang, additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Gorelik, Mark, additional, Abril, Andy, additional, Langford, Carol, additional, Maz, Mehrdad, additional, Chung, Sharon A., additional, and Mustafa, Reem A., additional
- Published
- 2021
- Full Text
- View/download PDF
46. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis
- Author
-
Maz, Mehrdad, primary, Chung, Sharon A., additional, Abril, Andy, additional, Langford, Carol A., additional, Gorelik, Mark, additional, Guyatt, Gordon, additional, Archer, Amy M., additional, Conn, Doyt L., additional, Full, Kathy A., additional, Grayson, Peter C., additional, Ibarra, Maria F., additional, Imundo, Lisa F., additional, Kim, Susan, additional, Merkel, Peter A., additional, Rhee, Rennie L., additional, Seo, Philip, additional, Stone, John H., additional, Sule, Sangeeta, additional, Sundel, Robert P., additional, Vitobaldi, Omar I., additional, Warner, Ann, additional, Byram, Kevin, additional, Dua, Anisha B., additional, Husainat, Nedaa, additional, James, Karen E., additional, Kalot, Mohamad A., additional, Lin, Yih Chang, additional, Springer, Jason M., additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Turner, Amy S., additional, and Mustafa, Reem A., additional
- Published
- 2021
- Full Text
- View/download PDF
47. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
- Author
-
Chung, Sharon A., primary, Langford, Carol A., additional, Maz, Mehrdad, additional, Abril, Andy, additional, Gorelik, Mark, additional, Guyatt, Gordon, additional, Archer, Amy M., additional, Conn, Doyt L., additional, Full, Kathy A., additional, Grayson, Peter C., additional, Ibarra, Maria F., additional, Imundo, Lisa F., additional, Kim, Susan, additional, Merkel, Peter A., additional, Rhee, Rennie L., additional, Seo, Philip, additional, Stone, John H., additional, Sule, Sangeeta, additional, Sundel, Robert P., additional, Vitobaldi, Omar I., additional, Warner, Ann, additional, Byram, Kevin, additional, Dua, Anisha B., additional, Husainat, Nedaa, additional, James, Karen E., additional, Kalot, Mohamad A., additional, Lin, Yih Chang, additional, Springer, Jason M., additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Turner, Amy S., additional, and Mustafa, Reem A., additional
- Published
- 2021
- Full Text
- View/download PDF
48. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa
- Author
-
Chung, Sharon A., primary, Gorelik, Mark, additional, Langford, Carol A., additional, Maz, Mehrdad, additional, Abril, Andy, additional, Guyatt, Gordon, additional, Archer, Amy M., additional, Conn, Doyt L., additional, Full, Kathy A., additional, Grayson, Peter C., additional, Ibarra, Maria F., additional, Imundo, Lisa F., additional, Kim, Susan, additional, Merkel, Peter A., additional, Rhee, Rennie L., additional, Seo, Philip, additional, Stone, John H., additional, Sule, Sangeeta, additional, Sundel, Robert P., additional, Vitobaldi, Omar I., additional, Warner, Ann, additional, Byram, Kevin, additional, Dua, Anisha B., additional, Husainat, Nedaa, additional, James, Karen E., additional, Kalot, Mohamad, additional, Lin, Yih Chang, additional, Springer, Jason M., additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Turner, Amy S., additional, and Mustafa, Reem A., additional
- Published
- 2021
- Full Text
- View/download PDF
49. The Excessively Clotting Cancer Patient
- Author
-
Gomes, Marcelo P. Villa-Forte, primary
- Published
- 2013
- Full Text
- View/download PDF
50. ENTRE TRAMAS E DADOS: DA EXPERIÊNCIA NARRATIVA À SUBJETIVIDADE QUANTIFICADA EM CERTA POÉTICA CONTEMPORÂNEA
- Author
-
LEONARDO NABUCO VILLA FORTE
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.